ArticleRSC advances2023
Double cross-linked transparent superhydrophilic coating capable of anti-fogging even after abrasion and boiling.
Article in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 12 citations in OpenAlex.
- Tunable, permanent and instantly available super-wettability states on metal surfaces by laser texturing and plasma coating.Scientific reports · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The commercial application of surfaces with superhydrophilic (SHPL) properties is well known as an efficient strategy to address problems such as anti-fogging, anti-frosting, and anti-biological contamination. However, current SHPL coatings are limited by their poor water and abrasion resistances. Thus, herein, to solve these problems active glass was employed as a substrate, and a stable and transparent SHPL solution was prepared
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.